Name
SUCRALFATE
Mode of Action
IT FORMS A GEL WHICH IS RELATIVELY IMPERMEABLE TO ACID ON THE ULCER, BILE REFLUX, CHRONIC GASTRITIS. IT IS A BASIC ALUMINIUM SALT OF SULFATED SUCROSE, INHERENTLY VISCOUS IN ACIDIC MEDIUM, POLYMERIZING INTO A STICKY GET LIKE CONSISTENCY. IT PRECIPITATES SURFACE PROTEINS AT ULCER BASE AND ACTS AS ACID RESISTANT PHYSICAL BARRIER PREVENTING ACID, PEPSIN AND BILE FROM COMING IN CONTACT WITH THE ULCER BASE. IT SHOULD BE USED WITH CAUTION IN PATIENTS UNDER INTENSIVE CARE (IMPORTANT: REPORTS OF BEZOAR FORMATION). ADMINISTRATION OF SUCRALFATE AND ENTERAL FEEDS SHOULD BE SEPARATED BY 1 HOUR
Dosage
BENIGN GASTRIC AND DUODENAL ULCERATION AND CHRONIC GASTRITIS, ADULT AND CHILD OVER 15 YEARS, 2 G TWICE DAILY (ON RISING AND AT BEDTIME) OR 1 G 4 TIMES DAILY 1 HOUR BEFORE MEALS AND AT BEDTIME, TAKEN FOR 4 - 6 WEEKS OR IN RESISTANT CASES UP TO 12 WEEKS; MAX. 8 G DAILY PROPHYLAXIS OF STRESS ULCERATION, ADULT AND CHILD OVER 15 YEARS, 1 G 6 TIMES DAILY; MAX. 8 G DAILY CHILDREN :- NOT RECOMMENDED.
Drug Group
[ALUMINIUM SALT] , [ANTACID]
Cross Reaction
REDUCE ABSORPTION OF TETRACYCLINES PHENYTOIN, CIMETIDINE, RANITIDINE, DIGOXIN, KETOCONAZOLE, WARFARIN, FLUOROQUINOLONES ANTIBIOTICS, QUINIDIEN, THEOPHYLLINE, THYROXINE AVOID MEDICINES, WITHIN 3 HRS OF SUCRALFATE.
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph